BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2019 6:46:23 AM | Browse: 808 | Download: 1782
 |
Received |
|
2019-02-26 02:15 |
|
Peer-Review Started |
|
2019-02-27 11:26 |
|
To Make the First Decision |
|
2019-04-12 00:28 |
|
Return for Revision |
|
2019-04-24 07:27 |
|
Revised |
|
2019-05-05 16:15 |
|
Second Decision |
|
2019-07-26 10:05 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-07-30 18:01 |
|
Articles in Press |
|
2019-07-30 18:01 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-08-09 18:53 |
|
Typeset the Manuscript |
|
2019-08-21 00:50 |
|
Publish the Manuscript Online |
|
2019-08-21 06:46 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019 Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gokhan Ozyigit, Pervin Hurmuz, Deniz Yüce and Fadıl Akyol |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gokhan Ozyigit, MD, Chairman, Full Professor, Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara 06100, Türkiye. gozyigit@hacettepe.edu.tr |
| Key Words |
Prostate cancer; Androgen deprivation therapy; Radiotherapy; Testosterone; Castration; |
| Core Tip |
Castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment for non-metastatic prostate cancer is associated with better biochemical relapse free survival. Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment in metastatic prostate cancer (PC). In this study, we evaluated the effect of two different castrate testosterone levels, < 50 and < 20 ng/dL, on biochemical relapse free survival in patients with non-metastatic intermediate and high risk PC receiving definitive modern radiotherapy and androgen deprivation treatment. With a median follow up of 125 mo we found that castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment was found to be associated with better biochemical relapse free survival. |
| Publish Date |
2019-08-21 06:46 |
| Citation |
Ozyigit G, Hurmuz P, Yuce D, Akyol F. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. World J Clin Oncol 2019; 10(8): 283-292 URL: https://www.wjgnet.com/2218-4333/full/v10/i8/283.htm DOI: https://dx.doi.org/10.5306/wjco.v10.i8.283 |
| URL |
https://www.wjgnet.com/2218-4333/full/v10/i8/283.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v10.i8.283 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
